Women taking the “blue pill” (sildenafil citrate): such a big deal?
Authors Lo Monte G, Graziano A, Piva I, Marci R
Received 16 July 2014
Accepted for publication 18 August 2014
Published 7 November 2014 Volume 2014:8 Pages 2251—2254
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 6
Editor who approved publication: Professor Shu-Feng Zhou
Giuseppe Lo Monte, Angela Graziano, Isabella Piva, Roberto Marci
Department of Morphology, Surgery, and Experimental Medicine, University of Ferrara, Ferrara, Italy
Abstract: For years, phosphodiesterase type 5 inhibitors have been used for the treatment of erectile dysfunctions. Due to the similarities between male and female sexual response, several studies have assessed the effects of sildenafil citrate (Viagra®) in women affected by female sexual arousal disorder. The results are still conflicting and the drug is not devoid of adverse effects. Furthermore, female sexual arousal disorder is a heterogeneous condition whose underlying causes are difficult to diagnose and appropriate treatment requires a thorough sexual, psychological, and medical history along with specialist consultations. The clinician should pursue a global approach to the patient with sexual difficulties, while non-hormonal treatment such as phosphodiesterase type 5 inhibitors (ie, sildenafil citrate) should be kept as the last option.
Keywords: phosphodiesterase type 5 inhibitors, female sexual arousal disorder (FSAD), sildenafil citrate
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]